Latest research on Paliperidone

Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006.

Latest findings

Concerning medication, three patients were free of any antipsychotic medication, the others received mono- or dual therapy with atypical antipsychotic medication including Amisulpride (n = 2), Olanzapine (n = 11), Clozapine (n = 4), Quetiapine (n = 2), Ziprasidone (n = 1), Risperidone (n = 5), Aripiprazole (n = 2), Paliperidone (n = 3; cp. [source, 2016]
Seventy-five patients were taking atypical antipsychotics (Risperidone, Paliperidone, Clozapine, Aripiprazole, Ziprasidone, and/or Quetiapine) at a median Chlorpromazine equivalent dose of 349.20 (277.64) mg/day. [source, 2016]
In addition, we tested whether use of Haloperidol, Risperidone, Olanzapine, Clozapine, Quetiapine, Paliperidone or Aripiprazole was associated with QTc interval. [source, 2016]
Paliperidone extended-release (ER) is a once-daily atypical antipsychotic, approved in many countries, including People’s Republic of China, for the treatment of schizophrenia in adults. [source, 2016]
Major exclusion criteria for the study included: drug dependence (excluding Nicotine and Caffeine dependence) within 6 months before screening according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition, history of cardiovascular, respiratory, neurologic, renal, hepatic, endocrine, or immunologic diseases, presence of circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, heart rate <50 beats per minute, presence of congenital prolongation of the QT interval or demonstration of repeated prolonged QTc Fridericia interval >450 ms in >1 electrocardiogram (ECG), neuroleptic malignant syndrome and hypersensitivity to Risperidone, Paliperidone, or their excipients. [source, 2016]
Patients treated with Clozapine for treatment-refractory or treatment-resistant schizophrenia, monoamine oxidase inhibitor antidepressants within 4 weeks before screening, depot antipsychotic drugs within 120 days, Paliperidone Palmitate within 10 months or electroconvulsive therapy within 60 days before screening, and pregnant and lactating women, were all excluded from the study. [source, 2016]
There are a limited number of randomized controlled studies comparing Paliperidone ER and other antipsychotics in international publications. [source, 2016]
No RCTs have compared the functionality outcome between Paliperidone ER and Risperidone or Aripiprazole. [source, 2016]
Three 6-week studies identified the efficacy and safety of Paliperidone ER, and used Olanzapine 10 mg/d treatment to confirm trial validity; the pooled data showed that there was no significant difference in mean PSP score change from baseline to end point between Paliperidone ER and Olanzapine groups. [source, 2016]
The efficacy of Paliperidone ER is at least comparable to that of other antipsychotics, and it has a better safety profile than Risperidone, and less severe sedative and metabolic effects than Olanzapine. [source, 2016]